# Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer

> **NCT00137423** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 107 (actual)

## Conditions studied

- Carcinoma, Renal Cell Metastasis

## Interventions

- **DRUG:** SU011248 (sunitinib)

## Key facts

- **NCT ID:** NCT00137423
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2007-09
- **Final completion:** 2008-05
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2009-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00137423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00137423, "Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00137423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*